Graff JN - Search Results

1

Fay EK, Graff JN. Fay EK, et al. Among authors: graff jn. Cancers (Basel). 2020 Jul 1;12(7):1752. doi: 10.3390/cancers12071752. Cancers (Basel). 2020. PMID: 32630247 Free PMC article. Review.

2

Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy.

Graff JN, Chamberlain ED. Graff JN, et al. Core Evid. 2014 Dec 18;10:1-10. doi: 10.2147/CE.S54712. eCollection 2015. Core Evid. 2014. PMID: 25565923 Free PMC article. Review.

3

Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer.

Graff JN, Alumkal JJ, Drake CG, Thomas GV, Redmond WL, Farhad M, Cetnar JP, Ey FS, Bergan RC, Slottke R, Beer TM. Graff JN, et al. Oncotarget. 2016 Aug 16;7(33):52810-52817. doi: 10.18632/oncotarget.10547. Oncotarget. 2016. PMID: 27429197 Free PMC article. Clinical Trial.

4

Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy.

Graff JN, Stein MN, Surana R, Al Rabadi L, Liu E, Fong L, Bailey S, Latour E, Newby TA, Moran AE, Beer TM. Graff JN, et al. Front Oncol. 2020 Aug 7;10:1381. doi: 10.3389/fonc.2020.01381. eCollection 2020. Front Oncol. 2020. PMID: 32850444 Free PMC article.

5

Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study.

Graff JN, Mori M, Li H, Garzotto M, Penson D, Potosky AL, Beer TM. Graff JN, et al. J Urol. 2007 Apr;177(4):1307-12. doi: 10.1016/j.juro.2006.11.054. J Urol. 2007. PMID: 17382720 Clinical Trial.

6

The role of C-reactive protein in prostate cancer.

Graff JN, Beer TM. Graff JN, et al. Cancer. 2013 Sep 15;119(18):3262-4. doi: 10.1002/cncr.28211. Epub 2013 Jul 1. Cancer. 2013. PMID: 23817779 Free article. No abstract available.

7

Targeted therapy in prostate cancer: is there hope beyond the androgen receptor?

Alumkal JJ, Graff JN, Beer TM. Alumkal JJ, et al. Among authors: graff jn. Oncology (Williston Park). 2013 Jul;27(7):628, 630, 637-8. Oncology (Williston Park). 2013. PMID: 23977755 No abstract available.

8

Sustained complete response to CTLA-4 blockade in a patient with metastatic, castration-resistant prostate cancer.

Graff JN, Puri S, Bifulco CB, Fox BA, Beer TM. Graff JN, et al. Cancer Immunol Res. 2014 May;2(5):399-403. doi: 10.1158/2326-6066.CIR-13-0193. Epub 2014 Feb 3. Cancer Immunol Res. 2014. PMID: 24795352 Free PMC article.

9

Pharmacotherapeutic management of metastatic, castration-resistant prostate cancer in the elderly: focus on non-chemotherapy agents.

Graff JN, Beer TM. Graff JN, et al. Drugs Aging. 2014 Dec;31(12):873-82. doi: 10.1007/s40266-014-0224-y. Drugs Aging. 2014. PMID: 25387443 Free PMC article. Review.

10

A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer.

Alumkal JJ, Slottke R, Schwartzman J, Cherala G, Munar M, Graff JN, Beer TM, Ryan CW, Koop DR, Gibbs A, Gao L, Flamiatos JF, Tucker E, Kleinschmidt R, Mori M. Alumkal JJ, et al. Among authors: graff jn. Invest New Drugs. 2015 Apr;33(2):480-9. doi: 10.1007/s10637-014-0189-z. Epub 2014 Nov 29. Invest New Drugs. 2015. PMID: 25431127 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

80 results

Search Page